Resistant Pseudomonas: Is One Active Antibiotic Enough?

What did COVID-19 reveal about antibiotic-resistant infections?

The CDC's COVID-19 and antimicrobial resistance page describes historical surveillance findings, rather than a newly announced October study. Resistant hospital-onset infections and associated deaths increased at least 15% from 2019 to 2020 across seven pathogens. Longer hospital stays, greater use of catheters and ventilators, staffing shortages and challenges maintaining infection prevention contributed to the conditions in which resistant organisms could spread. [CDC pandemic review](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html)

A subsequent CDC analysis found a combined 20% pandemic-era increase across six categories of resistant bacterial hospital-onset infections, with a peak in 2021 and levels still above the pre-pandemic baseline in 2022. Multidrug-resistant Pseudomonas aeruginosa was among those tracked. These population findings establish the scale of the treatment challenge; they do not demonstrate that prescribing additional antibiotics improves an individual patient's outcome. [CDC surveillance update](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html)

When is one treatment enough for resistant Pseudomonas?

IDSA guidance advises against routinely adding another antibiotic when difficult-to-treat Pseudomonas is susceptible to a recommended newer treatment, such as ceftolozane–tazobactam or cefiderocol. Adding an agent such as tobramycin has not demonstrated better outcomes in this setting and increases exposure to adverse effects. [IDSA treatment guidance](https://www.idsociety.org/practice-guideline/amr-guidance/)

Timing matters: initial combination treatment may improve the chance of providing an active drug before susceptibility results arrive. Continuing it afterward is a separate decision. Randomized trials comparing newer beta-lactam treatments alone against the same treatment plus another antibiotic are lacking; observational studies have not established a survival advantage for the combination. [IDSA evidence assessment](https://www.idsociety.org/practice-guideline/amr-guidance/)

What do clinical trials show about adding an aminoglycoside?

A 2014 Cochrane review included 69 trials involving 7,863 participants. Among trials using the same beta-lactam antibiotic in both groups, adding an aminoglycoside did not produce a statistically clear difference in deaths. Kidney toxicity was more frequent with combination treatment. The biological appeal of attacking bacteria through different mechanisms therefore did not translate into an established survival benefit. [Cochrane systematic review](https://doi.org/10.1002/14651858.CD003344.pub3)

The limitations are substantial. The review searched evidence through November 2013, evaluated older regimens and included too few Pseudomonas cases to resolve outcomes reliably for that subgroup. Mortality evidence was rated low quality, largely because of imprecision. Its findings support caution about unnecessary additional drugs, but cannot establish equivalence for every modern resistant infection or replace organism-specific treatment guidance. [Cochrane findings and limitations](https://doi.org/10.1002/14651858.CD003344.pub3)